HT-ALZ Showed Improvement on Several Tests of Cognitive Function
HT-ALZ Showed Positive Benefits with Reductions in Anxiety
Completed Dose Response Study Leads Hoth to Begin Formulation Development
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-ALZ, a therapeutic in development for the treatment of Alzheimer's Disease ("AD"), achieved positive preclinical end points in a study conducted at Washington University, St. Louis.
https://finance.yahoo.com/news/hoth-therapeutics-announces-positive-preclinical-121300627.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.